Lacosamid Hikma

Lacosamide, the active ingredient in Lacosamid Hikma, is an anticonvulsant presented as an intravenous formulation for injection use. It is employed in the management of partial‑onset seizures, typically as adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. Our global network ensures reliable access and consistent quality for healthcare providers.

Lacosamide is indicated for the treatment of focal seizure disorders and is used as adjunctive therapy in epilepsy.

- Partial-onset seizures: Reduces seizure frequency when added to existing antiepileptic regimen. - Adjunctive therapy for epilepsy: Enhances overall seizure control in patients whose seizures are not fully managed by other drugs.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Headache: transient cranial pain. - Fatigue: feeling unusually tired. - Vision disturbances: blurred or double vision. - Tremor: involuntary shaking of limbs.

Serious or Rare Side Effects: - Cardiac arrhythmias: abnormal heart rhythm, including PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Respiratory depression: reduced breathing effort, especially with rapid IV administration. - Hypotension: marked drop in blood pressure. - Supraventricular tachycardia: rapid heart rate originating above the ventricles.

When prescribing lacosamide, clinicians should consider several safety aspects.

- Cardiac monitoring: assess PR interval and heart rhythm before and during therapy. - Renal impairment: adjust use in patients with severe kidney dysfunction. - Hepatic dysfunction: consider caution in moderate to severe liver disease. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory effects. - Pregnancy and lactation: use only if benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with several medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Carbamazepine: may reduce lacosamide plasma levels. - Phenytoin: can lower lacosamide exposure, decreasing efficacy. - Rifampin: strong enzyme inducer that markedly decreases lacosamide concentrations.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine, omeprazole): may increase lacosamide levels. - Other sodium channel blockers (e.g., lamotrigine): risk of additive CNS effects. - Anticoagulants (e.g., warfarin): monitor for altered coagulation parameters.